Related Experiment Videos
Drug targets in Menkes disease - prospective developments
Hiroko Kodama1, Yan-Hong Gu, Makiko Mizunuma
1Department of Pediatrics, Teikyo University School of Medicine, 11-1, Kaga-2, Itabashi-ku, Tokyo 173-8605, Japan. hkodama@med.teikyo-u.ac.jp
Expert Opinion on Therapeutic Targets
|January 24, 2003
Summary
Menkes disease (MNK) is a copper transport disorder. Current treatments improve neurological outcomes if started early, but not connective tissues, necessitating new therapeutic targets.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Menkes disease (MNK) is an X-linked recessive disorder caused by a defect in copper transport.
- This defect impairs copper delivery to the Golgi apparatus, leading to cellular copper deficiency.
- Key features include neurological degeneration, connective tissue problems, and hair abnormalities due to reduced copper-dependent enzyme activity.
Purpose of the Study:
- To review current knowledge of Menkes disease and its variants.
- To evaluate the efficacy and limitations of existing treatments.
- To identify potential therapeutic targets for improved treatment strategies.
Main Methods:
- Literature review of Menkes disease pathophysiology and treatment.
- Analysis of current treatment outcomes with copper-histidine complex.
- Identification of unmet needs in Menkes disease management.
Main Results:
- Subcutaneous copper-histidine complex can prevent neurological degeneration if initiated neonatally.
- Late treatment initiation does not prevent neurological damage.
- Current treatments do not resolve connective tissue disorders linked to lysyl oxidase deficiency.
Conclusions:
- Novel therapeutic approaches are needed to deliver copper effectively to the Golgi apparatus.
- Targeting copper delivery within cells may overcome limitations of current Menkes disease treatments.
- Further research into therapeutic targets is crucial for addressing the multifaceted nature of Menkes disease.